Nichole M. Ryba, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 2913 Windmill Rd Ste 7, Sinking Spring, PA 19608 Phone: 610-288-2908 Fax: 610-898-4832 |
Katelyn Anderson, PAC Physician Assistant Medicare: Medicare Enrolled Practice Location: 4860 Penn Ave, Sinking Spring, PA 19608 Phone: 484-659-1520 |
Nancy Manubay, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 4400 Penn Ave, Sinking Spring, PA 19608 Phone: 610-670-2522 Fax: 610-670-7736 |
Kate Ferrarello, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 2913 Windmill Rd, Spring Commons; Suite 7, Sinking Spring, PA 19608 Phone: 610-288-2908 Fax: 610-898-4832 |
Jennifer Lynn Dankel, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 4906 Penn Ave Ste 202, Sinking Spring, PA 19608 Phone: 610-484-3761 Fax: 610-484-3549 |
News Archive
Patients often take drugs to lower stomach acid and reduce the chances they will develop ulcers from taking their anti-inflammatory drugs for conditions such as arthritis, but the combination may be causing major problems for their small intestines, McMaster researchers have found.
An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.
World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacorâ„¢ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.
Antibodies are a powerful weapon system in defending our body against invaders such as bacteria and viruses. Each antibody consists of four polypeptide chains: two heavy chains and two light chains joined to form a Y-shaped molecule.
Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.
› Verified 7 days ago